Susan E Henry

US Patent:

59087528, Jun 1, 1999

Filed:

May 7, 1997

Appl. No.:

8/852450

Inventors:

Susan A. Henry - Pittsburgh PA
Jana L. Patton - Pittsburgh PA
Peter Griac - Bratislava, SK
Sepp D. Kohlwein - Graz, AT

Assignee:

Carnegie Mellon University - Pittsburgh PA

International Classification:

C12Q 102
C12Q 168
C12N 118

US Classification:

435 6

Abstract:

Methods are provided for increased and controlled production of choline and inositol, choline and inositol metabolites, and choline- and inositol-containing phospholipids in yeast, comprising the step of increasing phosphatidylcholine (PC) turnover in yeast. Methods are also provided for detecting phospholipase D-mediated turnover of phosphatidylcholine in vivo in yeast, comprising an assay for choline excretion.

US Patent:

55299121, Jun 25, 1996

Filed:

May 30, 1995

Appl. No.:

8/453477

Inventors:

Susan A. Henry - Pittsburgh PA
Michael J. White - Pittsburgh PA

Assignee:

Carnegie Mellon University - Pittsburgh PA

International Classification:

C12P 702
C12P 764
C12N 912
C12N 119

US Classification:

435155

Abstract:

A yeast cell, preferably Saccharomyces cerevisiae, which contains a functional stable recombinant DNA sequence that does not allow for the encoding of a negative regulator of phospholipid biosynthesis therein and which has multiple copies of an INO1 gene. In a preferred embodiment, the recombinant DNA sequence is an OPI1 gene deletion which results in the deregulation of inositol or inositol-containing metabolites such as inositol-1-phosphate synthase. Moreover, there is a method for obtaining inositol, inositol-containing metabolites or phospholipids such as myo-inositol or inositol-1-phosphate. The method comprises the steps of genetically engineering a stable yeast cell, preferably Saccharomyces cerevisiae, to continually produce inositol, inositol-containing metabolites or phospholipids. Additionally, there is the step of then generating the inositol, inositol-containing metabolites or phospholipids. In a preferred embodiment, the genetically engineering step includes the step of altering the negative regulatory step involved in phospholipid biosynthesis to overproduce inositol, inositol-containing metabolites or phospholipids such as myo-inositol.

US Patent:

55997015, Feb 4, 1997

Filed:

May 30, 1995

Appl. No.:

8/453461

Inventors:

Susan A. Henry - Pittsburgh PA
Michael J. White - Pittsburgh PA

Assignee:

Carnegie Mellon University - Pittsburgh PA

International Classification:

C12P 702
C12P 764
C12N 912
C12N 119

US Classification:

435155

Abstract:

A yeast cell, preferably Saccharomyces cerevisiae, which contains a functional stable recombinant DNA sequence that does not allow for the encoding of a negative regulator of phospholipid biosynthesis therein. In a preferred embodiment, the recombinant DNA sequence is an opil gene deletion which results in the deregulation of inositol or inositol-containing metabolites such as inositol-1-phosphate synthase. Moreover, there is a method for obtaining inositol, inositol-containing metabolites or phospholipids such as myo-inositol or inositol-1-phosphate. The method comprises the steps of genetically engineering a stable yeast cell, preferably Saccharomyces cerevisiae, to continually produce inositol, inositol-containing metabolites or phospholipids. Additionally, there is the step of then generating the inositol, inositol-containing metabolites or phospholipids. In a preferred embodiment, the genetically engineering step includes the step of altering the negative regulatory step involved in phospholipid biosynthesis to overproduce inositol, inositol-containing metabolites or phospholipids such as myo-inositol.